Most Read

This review could potentially lead to the approval of the first combination treatment offering an alternative to platinum-containing chemotherapy as the first-line treatment for locally advanced or metastatic

ATA3219 utilises allogeneic T cells to act on the CD19 antigen found on B cells, which are implicated in B-cell mediated autoimmune diseases such as systemic lupus erythematosus

Ally Bridge Group led the funding round, which saw contributions from healthcare focused and mutual fund institutional investors. New investors comprised Nextech Invest, funds and accounts advised by

Earlier in January, Precision announced the completion of a strategic deal with TG Therapeutics for the exclusive licence to develop azer-cel for autoimmune diseases and other non-cancer indications.

This designation is a significant milestone for the company as it aims to develop treatments for rare hematologic conditions. DISC-3405, an anti-Transmembrane Serine Protease 6 (TMPRSS6) monoclonal antibody,

The investment will also enable the company to enhance the outcomes in pharma manufacturing by scaling its operations and improve customer service. A growth equity fund specialising in

The collaboration will leverage Samsung Biologics’ expertise in antibody development and drug substance manufacturing services. Under the agreement, Samsung Biologics will provide complete services for ADC development and

Researchers at Camino Pharma, Sanford Burnham Prebys and the University of California San Diego School of Medicine received the three-year grant. The funds will facilitate longer toxicology studies

Under the deal terms, Bluejay will have the sole licence to Exicure’s patents relevant to hepatitis. Bluejay made an initial payment to Exicure following the deal execution. In